Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zentius Flash is an orally disintegrating tablet (ODT) combination therapy containing 600 mg of calcium carbonate and 400 I.U. of vitamin D3 (cholecalciferol). Developed and marketed by ITF İlaç Sanayi ve Ticaret in Turkey and manufactured by Italfarmaco S.p.A. in Italy, it is indicated for the prevention and treatment of calcium and vitamin D deficiencies, as well as an adjunct in the management of osteoporosis. The ODT formulation is designed to dissolve quickly in the mouth without the need for water, facilitating ease of use and potentially improving patient adherence in populations with swallowing difficulties. It is regulated as a prescription medication (Beyaz Reçete) in Turkey.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zentius Flash.